A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB 111077 in Subjects with Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs OPB 111077 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Korea Otsuka Pharmaceutical
- 07 May 2017 Status changed from recruiting to discontinued.
- 28 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
- 04 Oct 2013 New trial record